Printer Friendly

Articles from M2 Pharma (October 12, 2017)

1-17 out of 17 article(s)
Title Author Type Words
AbbVie to Present Mavyret (glecaprevir/pibrentasvir) Data. 225
Ardelyx Study of Tenapanor for IBS-C Hits Demonstrates Ability to Normalize Bowel Function. 123
Beacon Health Options elects Michael Ramseier as EVP & market president. 138
BioPharmX and Wellman Center for Photomedicine Researchers Develop Optical Imaging Technique to Visualize Drug Delivery. 275
Caris Life Sciences' Precision Oncology Alliance Adds St. Jude Crosson Cancer Institute. 334
Harbour BioMed licenses transgenic platform to Innovent Biologics. 173
Janssen Biotech submits NDA with the US FDA for apalutamide for non-metastatic castration-resistant prostate cancer. 240
Janssen Submits NDA to US FDA for Apalutamide for Treatment of Non-Metastatic Castration-Resistant Prostate Cancer. 197
Longevity Biotech wins US patent for hybridtide platform technology for stabilized peptide therapeutics. 208
MabVax Therapeutics Begins Patient Enrollment at Memorial Sloan Kettering Cancer Center for Trial of Radioimmunotherapy for Advanced Pancreatic, Colon and Lung Cancers. 296
Neuronetics to sell and distribute NeuroStar Advanced Therapy system for Major Depressive Disorder (MDD) in Japan upon Shonin approval. 237
Philogen granted IND approval by FDA for Phase 3 registration trial with investigational melanoma drug. 222
Samsung BioLogics awarded first US FDA approval at the world's largest biologics drug substance plant. 263
Sanofi to expand vaccine manufacturing site in Val de Reuil, France. 170
Targovax ASA announces one-year data for modified cohort of TG01 trial. 262
Upsher-Smith unveils generic Aromasin (Exemestane) Tablet in the US. 117
VLP Therapeutics awarded Phase 1 SBIR grant to support novel virus-like particle vaccine-based cancer immunotherapy. 230

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters